A Comparison of Multimodality Treatment: Two and Four Courses of Neoadjuvant Chemotherapy Using S-1/CDDP or S-1/CDDP/Docetaxel Followed by Surgery and S-1 Adjuvant Chemotherapy for Macroscopically Resectable Serosa-positive Gastric Cancer: A Randomized Phase II Trial (COMPASS-D Trial)

被引：14

作者：

Yoshikawa, Takaki ^{[1
]}

Taguri, Masataka ^{[2
]}

Sakuramoto, Shinichi ^{[3
]}

Kunisaki, Chikara ^{[4
]}

Fukunaga, Tetsu ^{[5
]}

Ito, Seiji ^{[6
]}

Cho, Haruhiko

Tanabe, Kazuaki ^{[7
]}

Nishikawa, Kazuhiro ^{[8
]}

Matsui, Takanori ^{[9
]}

Morita, Satoshi ^{[2
]}

Tsuburaya, Akira

机构：

[1] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Asahi Ku, Yokohama, Kanagawa 2410815, Japan

[2] Yokohama City Univ, Med Ctr, Dept Biostat & Epidemiol, Yokohama, Kanagawa 232, Japan

[3] Kitasato Univ, Dept Surg, Sagamihara, Kanagawa 228, Japan

[4] Yokohama City Univ, Med Ctr, Dept Surg, Yokohama, Kanagawa 232, Japan

[5] St Marianna Univ, Dept Gastroenterol & Gen Surg, Kawasaki, Kanagawa, Japan

[6] Aichi Canc Ctr Hosp, Dept Surg Gastroenterol, Nagoya, Aichi 464, Japan

[7] Hiroshima Univ, Dept Gastrointestinal Surg, Hiroshima, Japan

[8] Osaka Gen Med Ctr, Dept Surg, Osaka, Japan

[9] Aichi Hosp, Aichi Canc Ctr, Dept Gastrointestinal Surg, Okazaki, Aichi, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 42卷 / 01期

关键词：

gastric; neoadjuvant chemotherapy; Phase II; cancer; PLUS CISPLATIN; PERIOPERATIVE CHEMOTHERAPY; PACLITAXEL; MULTICENTER; ADENOCARCINOMA; THERAPY;

D O I：

10.1093/jjco/hyr166

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This randomized Phase II trial will compare the outcome of neoadjuvant chemotherapy using two and four courses of S-1 plus cisplatin or S-1 plus cisplatin plus docetaxel by a two-by-two factorial design for patients with macroscopically resectable serosa-positive gastric cancer. After neoadjuvant chemotherapy, patients will receive D2 gastrectomy followed by S-1 chemotherapy for 1 year postoperatively. The primary endpoint is the 3-year overall survival. The sample size is 120 for the two hypotheses: the superiority of four courses compared with two courses and the superiority of S-1 plus cisplatin plus docetaxel compared with S-1 plus cisplatin. This trial will be able to define the more suitable number of cycles and better regimen of neoadjuvant chemotherapy for gastric cancer.

引用

页码：74 / 77

页数：4

共 50 条

[1] Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer
Kochi, Mitsugu
Fujii, Masashi
Kanamori, Noriaki
Kaiga, Teruo
Takahashi, Toru
Kobayashi, Michiyo
Takayama, Tadatoshi
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2006, 132 (12) : 781 - 785
[2] Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer
Mitsugu Kochi
Masashi Fujii
Noriaki Kanamori
Teruo Kaiga
Toru Takahashi
Michiyo Kobayashi
Tadatoshi Takayama
Journal of Cancer Research and Clinical Oncology, 2006, 132 : 781 - 785
[3] Combination chemotherapy of S-1, docetaxel and CDDP for the treatment of advanced gastric cancer
Niitsu, Yoshiro
Takayama, Tetsuji
Sato, Yasushi
Sagawa, Tamotsu
Abe, Seichiro
Kato, Junji
ANNALS OF ONCOLOGY, 2006, 17 : 313 - 314
[4] BIOMARKER ANALYSIS OF WJOG4107 (A RANDOMIZED PHASE II TRIAL OF ADJUVANT CHEMOTHERAPY WITH S-1 VS CDDP + S-1 IN NSCLC)
Takeda, M.
Mitsudomi, T.
Nishio, K.
Iwamoto, Y.
Yamanaka, T.
Yoshioka, H.
Tsukamoto, S.
Koike, T.
Nakagawa, K.
Nakanishi, Y.
ANNALS OF ONCOLOGY, 2013, 24
[5] A randomized phase III study of neoadjuvant chemotherapy with docetaxel(D), oxaliplatin(O), and S-1(S) (DOS) followed by surgery and adjuvant S-1 vs. surgery and adjuvant S-1 for resectable advanced gastric cancer (PRODIGY).
Kang, Yoon-Koo
Yook, Jeong Hwan
Ryu, Min-Hee
Lee, Jong Seok
Park, Youngkyu
Chung, Ik-Joo
Jung, Minkyu
Kim, Young Woo
Kim, Mi-Jung
Oh, Sang Cheul
Kim, Samyong
Kim, Jong Gwang
Song, Hong-Suk
Ryu, Seung Wan
Roh, Sang Young
Kook, Myeong-Cherl
Shim, Kyoo Jung
Lee, Jeehyun
Kim, Gyunji
Noh, Sung Hoon
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[6] A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
Park, Inkeun
Ryu, Min-Hee
Choi, Yoon Hee
Kang, Hyo Jeong
Yook, Jeong Hwan
Park, Young Soo
Kim, Hyun Jin
Jung, Hwoon-Yong
Lee, Gin Hyug
Kim, Kab Choong
Kim, Byung Sik
Kang, Yoon-Koo
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 815 - 823
[7] A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma
Inkeun Park
Min-Hee Ryu
Yoon Hee Choi
Hyo Jeong Kang
Jeong Hwan Yook
Young Soo Park
Hyun Jin Kim
Hwoon-Yong Jung
Gin Hyug Lee
Kab Choong Kim
Byung Sik Kim
Yoon-Koo Kang
Cancer Chemotherapy and Pharmacology, 2013, 72 : 815 - 823
[8] Primary results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for advanced gastric cancer
Hayashi, Tsutomu
Yoshikawa, Takaki
Sakamaki, Kentaro
Nishikawa, Kazuhiro
Fujitani, Kazumasa
Tanabe, Kazuaki
Misawa, Kazunari
Matsui, Takanori
Miki, Akira
Nemoto, Hiroshi
Fukunaga, Tetsu
Kimura, Yutaka
Hihara, Jun
ANNALS OF GASTROENTEROLOGICAL SURGERY, 2020, 4 (05): : 540 - 548
[9] Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S-1(S) (DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC) (PRODIGY)
Kang, Y-K.
Yook, J. H.
Park, Y-K.
Kim, Y-W.
Kim, J.
Ryu, M-H.
Rha, S. Y.
Chung, I-J.
Kim, I-H.
Oh, S. C.
Yoo, C-H.
Choi, J-H.
Zang, D. Y.
Kim, G.
Lee, Y.
Noh, S-H.
ANNALS OF ONCOLOGY, 2019, 30
[10] Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer
Aoyama, T.
Nishikawa, K.
Fujitani, K.
Tanabe, K.
Ito, S.
Matsui, T.
Miki, A.
Nemoto, H.
Sakamaki, K.
Fukunaga, T.
Kimura, Y.
Hirabayashi, N.
Yoshikawa, T.
ANNALS OF ONCOLOGY, 2017, 28 (08) : 1876 - 1881

← 1 2 3 4 5 →